Table 5.
Postoperative complications
| Complications | Diprospan group | Placebo group | Control group | P value* | P value*? |
| Pulmonary | |||||
| -Bronchospasm | 2 | 3 | 1 | ||
| -Pneumonia | 1 | 1 | 1 | ||
| -Atelectasis | 1 | 0 | 0 | ||
| -Pleural effusion | 1 | 0 | 2 | ||
| -Pneumothorax | 0 | 1 | 0 | ||
| -Respiratory failure | 1 | 1 | 1 | ||
| Total pulmonary | 6(20%) | 6 (20%) | 5 (10%) | 0.56 | 0.02 |
| Nonpulmonary | |||||
| Major | |||||
| - Wound infection | 2 | 4 | 0 | ||
| - Acute renal failure | 1 | 0 | 0 | ||
| - Stroke | 1 | 2 | 0 | ||
| - Sepsis | 0 | 1 | 0 | ||
| - Re-surgery | 1 | 1 | 2 | ||
| Total major | 5 (17%) | 8 (26%) | 2 (7%) | 0.8 | 0.03 |
| Minor | |||||
| - Atrial | 11 | 8 | 1 | ||
| tachyarrhythmias - | |||||
| Superficial wound | 4 | 3 | 4 | ||
| infection | |||||
| - Transient oliguria | 1 | 2 | 3 | ||
| - Urinary tract infection | 0 | 1 | 0 | ||
| - Acute gout | 0 | 1 | 0 | ||
| Total minor | 16 (53%) | 15 (50%) | 8 (27%) | 0.1 | 0.01 |
| Total nonpulmonary | 21 (70%) | 23 (76%) | 10 (33%) | 0.79 | 0.01 |
* Between Diprospan and placebo groups.
** Between Control and COPD groups.